Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT Glioblastoma Trial (GlobeNewswire) - Oct 29, 2020 - "Plus Therapeutics...announced that it has treated the first patient in the sixth and final cohort of its National Cancer Institute (NCI)-supported, multi-center ReSPECT™ Phase 1 dose-finding clinical trial evaluating Rhenium NanoLiposomes (RNL™) for the treatment of recurrent glioblastoma (GBM). Initiation of the sixth dose cohort follows successful completion of the fifth cohort and clearance from the ReSPECT trial’s Data and Safety Monitoring Board (DSMB)....Plus Therapeutics will be presenting data from the ReSPECT clinical trial at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually November 19-21, 2020....ReSPECT is currently supported by an award from the NCI. The Company plans to complete enrollment in the Phase 1 trial by the end of 2020..."
DSMB • Enrollment status • P1 data • Trial status • Glioblastoma • Glioma • Oncology
|